1-9 of 9
Tara Kendall
Close
Sort by
Journal Articles

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Tara Kendall, PA, Ammar Al-Zoubi, MD, Yasser Khaled, MD, Shin Mineishi, MD, Christine Brozo, Erica Campagnaro, MD, Moshe Talpaz, Mark S. Kaminski, MD
Journal: Blood
Blood (2008) 112 (11): 3713.
https://doi.org/10.1182/blood.V112.11.3713.3713
Published: 2008
Journal Articles

Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar ® ) Correlates with Response to Therapy

Andrzej J. Jakubowiak, MD, PhD, Malathi Hari, PhD, Tara Kendall, PA, Yasser Khaled, MD, Shin Mineishi, MD, Ammar Al-Zoubi, MD, Mark S. Kaminski, MD, Ivan Maillard, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5176.
https://doi.org/10.1182/blood.V112.11.5176.5176
Published: 2008
Journal Articles

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Paul Richardson, MD, Todd M. Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Colleen Harvey, Christine Brozo, PA, Tara Kendall, PA, Amanda McAllister, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD, Kathy Giusti, MBA
Journal: Blood
Blood (2008) 112 (11): 3691.
https://doi.org/10.1182/blood.V112.11.3691.3691
Published: 2008
Journal Articles

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Paul Richardson, MD, Jeffrey Wolf, MD, Andrzej Jakubowiak, MD, PhD, Jeffrey Zonder, MD, Sagar Lonial, MD, David H Irwin, MD, John Densmore, MD, PhD, Amrita Krishnan, MD, FACP, Noopur Raje, MD, Michael H. Bar, MD, Jeffrey P. Allerton, MD, Robert Schlossman, Irene M. Ghobrial, M.D., Nikhil C. Munshi, MD, Thomas Martin, MD, Jacob Laubach, MD, Kathy Colson, RN, Sarah Dean, Deanna Tocco, Elizabeth Steinfield, RN, Tara Kendall, PA, Kimberly O’Riley, RN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 870.
https://doi.org/10.1182/blood.V112.11.870.870
Published: 2008
Journal Articles

Gene Expression Profiles (GEP) To Predict at Least Very Good Partial Response to Velcade, Doxil, and Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma.

Malathi Hari, James MacDonald, Judah Friedman, Tara Kendall, George Mulligan, Andrzej Jakubowiak
Journal: Blood
Blood (2007) 110 (11): 1489.
https://doi.org/10.1182/blood.V110.11.1489.1489
Published: 2007
Journal Articles

Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).

Andrzej Jakubowiak, Malathi Hari, Ammar Al-Zoubi, Tara Kendall, Yasser Khaled, Shin Mineishi, Mark Kaminski
Journal: Blood
Blood (2007) 110 (11): 4796.
https://doi.org/10.1182/blood.V110.11.4796.4796
Published: 2007
Journal Articles

Serum Free Light Chain Analysis Improves Monitoring of Multiple Myeloma Patients Receiving First-Line Therapy with the Combination of Velcade, Doxil, and Dexamethasone (VDD).

Daniel Lebovic, MD, Tara Kendall, PA-C, Christine Brozo, PA-C, Amanda McAllister, BS, Malathi Hari, PhD, Sairah Alvi, PhD, Ewan J.D. Robson, PhD, Andrzej J. Jakubowiak, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2736.
https://doi.org/10.1182/blood.V110.11.2736.2736
Published: 2007
Journal Articles

High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT).

Andrzej J. Jakubowiak, MD, PhD, Ammar Al-Zoubi, MD, Tara Kendall, PA-C, Judah Friedman, MD, Asra Ahmed, MD, Yasser Khaled, MD, Shin Mineishi, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2006) 108 (11): 3093.
https://doi.org/10.1182/blood.V108.11.3093.3093
Published: 2006
Journal Articles

Combination Therapy with Velcade, Doxil, and Dexamethasone (VDD) for Patients with Relapsed/Refractory Multiple Myeloma (MM).

Andrzej J. Jakubowiak, MD, PhD, Lindsey Brackett, PA-C, Tara Kendall, PA-C, Judah Friedman, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2005) 106 (11): 5179.
https://doi.org/10.1182/blood.V106.11.5179.5179
Published: 2005